ATRS - Antares Pharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.1200
+0.1950 (+6.67%)
At close: 4:00PM EDT

3.1201 0.00 (0.00%)
After hours: 4:50PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Long-term KST

Long-term KST

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close2.9250
Open2.9900
Bid3.1100 x 1800
Ask3.1900 x 2200
Day's Range2.9500 - 3.1900
52 Week Range1.6000 - 5.1300
Volume1,829,453
Avg. Volume1,572,379
Market Cap516.547M
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)-0.0040
Earnings DateMay 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why Is This Fast-Growing Biotech So Undervalued?
    Motley Fool

    Why Is This Fast-Growing Biotech So Undervalued?

    Why is a fast-growing company making one of the best testosterone replacement therapies on the market so underappreciated by investors?

  • GlobeNewswire

    Antares Pharma to Present at the Jefferies Virtual Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 10:00 a.m. Eastern Time. Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia).

  • Thomson Reuters StreetEvents

    Edited Transcript of ATRS earnings conference call or presentation 5-May-20 12:30pm GMT

    Q1 2020 Antares Pharma Inc Earnings Call

  • Antares Pharma Inc (ATRS) Q1 2020 Earnings Call Transcript
    Motley Fool

    Antares Pharma Inc (ATRS) Q1 2020 Earnings Call Transcript

    Before we begin, I'd like to remind you that some of our statements made during this conference call will contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. The company cautions investors not to place undue reliance on these forward-looking statements.

  • Why Antares Pharma Is Crashing 12.3% Today
    Motley Fool

    Why Antares Pharma Is Crashing 12.3% Today

    After the company reported mixed first-quarter financial results that were better than expected on the top line and worse than expected on the bottom line, shares in Antares Pharma (NASDAQ: ATRS) had tumbled 12.3% at 12 p.m. EST on Tuesday. The healthcare company delivered robust revenue growth in Q1 because of Xyosted, a long-lasting testosterone drug, and Teva Pharmaceutical Industries' (NYSE: TEVA) generic version of Mylan's EpiPen, which uses Antares technology.

  • GlobeNewswire

    Antares Pharma Reports First Quarter 2020 Operating and Financial Results

    First Quarter 2020 Revenue $33.1 Million, a 42% Increase Compared to First Quarter 2019 Generated $5.6 Million in Cash from Operations during the First Quarter 2020 EWING,.

  • GlobeNewswire

    Antares Pharma to Report First Quarter 2020 Operating and Financial Results

    EWING, N.J., April 28, 2020 -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its first quarter 2020 financial results and recent operating progress before.

  • Thomson Reuters StreetEvents

    Edited Transcript of ATRS earnings conference call or presentation 3-Mar-20 1:30pm GMT

    Q4 2019 Antares Pharma Inc Earnings Call

  • The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More
    Benzinga

    The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 2) * Forty Seven Inc (NASDAQ: FTSV)( announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD)) * IGM Biosciences Inc (NASDAQ: IGMS) * Iovance Biotherapeutics Inc (NASDAQ: IOVA) * Karyopharm Therapeutics Inc (NASDAQ: KPTI)(announced positive late-stage results for selinexor) * Passage Bio Inc (NASDAQ: PASG)(IPOed Friday) * Syneos Health Inc (NASDAQ: SYNH) * Trillium Therapeutics Inc (NASDAQ: TRIL)(moved in sympathy with Forty Seven, as it has a similar drug in the pipeline for solid tumor) * Zynex Inc. (NASDAQ: ZYXI)Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 2) * Aerie Pharmaceuticals Inc (NASDAQ: AERI) * AEterna Zentaris Inc. (NASDAQ: AEZS) * Akorn, Inc. (NASDAQ: AKRX) * ANI Pharmaceuticals Inc (NASDAQ: ANIP)(moved lower despite FDA nod for a generic version of Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) Alzheimer's related dementia drug) * Autolus Therapeutics Ltd - ADR (NASDAQ: AUTL) * Axovant Gene Therapies Ltd (NASDAQ: AXGT) * Black Diamond Therapeutics Inc (NASDAQ: BDTX) * Eagle Pharmaceuticals Inc (NASDAQ: EGRX) (reacted to its fourth-quarter results) * Evolus Inc (NASDAQ: EOLS) * EXACT Sciences Corporation (NASDAQ: EXAS) * GenMark Diagnostics, Inc (NASDAQ: GNMK) * Imv Inc (NASDAQ: IMV) * Neurometrix Inc (NASDAQ: NURO) * Portola Pharmaceuticals Inc (NASDAQ: PTLA) * Precigen Inc (NASDAQ: PGEN) * Taro Pharmaceutical Industries Ltd. (NYSE: TARO) * Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) * TherapeuticsMD Inc (NASDAQ: TXMD) * Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) * Viking Therapeutics Inc (NASDAQ: VKTX)Related Link: How The COVID-19 Outbreak Is Benefiting Biotech InvestorsStocks In Focus GenMark Starts Shipping COVID-19 Test Kits GenMark said it has begun shipping ePlex Research Use Only, or RUO, test kits to detect COVID-19 virus. The initial shipment will go to its Hong Kong distributor as well as several U.S. customers having access to clinical samples.Separately, the company reported fourth-quarter results, showing 24% year-over-year revenue growth and a narrower loss of 17 cents per share, while analysts estimated a loss of 16 cents per share.The stock jumped 21.65% to $4.27 in after-hours trading.Novartis' Sandoz Unit Agrees For $195M Settlement In Generics Price Fixing Probe Novartis AG's (NYSE: NVS) Sandoz unit said it has reached a resolution with the U.S. DoJ in a 3-year-long antitrust investigation carried out by the agency into the U.S. generic drug industry. Sandoz said the settlement pertains to instances of misconduct by the company between 2013 and 2015 with certain generic drugs sold in the U.S. As part of the agreement, Sandoz will pay $195 million.Unity Biotech Taps Former Biogen Executive as CEO Unity Biotechnology Inc (NASDAQ: UBX) announced the appointment of Anirvan Ghosh as CEO and member of the board, effective March 30. Ghosh was previously with as Biogen Inc (NASDAQ: BIIB) as SVP, Head of Research and Early Development.The company said current CEO Keith Leonard will step down from the role due to personal circumstances.KemPharm Filed Regulatory Application For ADHD Drug KemPharm Inc (NASDAQ: KMPH) said it has submitted a NDA for KP415, its investigational asset to treat attention deficit hyperactivity disorder, or ADHD. KP415 contains serdexmethylphenidate and KemPharm's prodrug d-methylphenidate.The stock jumped 37.61% to 45 cents in after-hours trading.CanFite Submits Safety Report Showing Favorable Safety Snd Risk-Benefit Ratios CAN FITE BIOPHARMA ADR REP 30 ORD (NYSE: CANF) announced submission of annual Drug Safety Update Reports to health regulatory agencies concerning Piclidenoson and Namodenoson, which show both investigational-stage drugs have favorable safety profiles and risk-benefit ratios in more than 1,500 patients.In premarket trading Tuesday, the shares were surging up 29.92% to $1.65.Thermo Fisher To Buy Qiagen For $10B In Cash Thermo Fisher Scientific Inc. (NYSE: TMO) announced a deal to buy molecular diagnostics company Qiagen NV (NYSE: QGEN) for 39 euros per share in cash or 9 billion euros ($10 billion).In premarket trading Tuesday, Qiagen shares were rallying 16.06% to $41.92 and Thermo Fisher shares were moving up 3.26% to $314.90,Alnylam Says Inherited Liver Enzyme Deficiency Drug Approved In Europe Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) said the European Commission has granted marketing authorization for GIVLAARI, an injection for subcutaneous use targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria in adults and adolescents aged 12 years and olderLily Assuages COVID-19 Concerns Eli Lilly And Co (NYSE: LLY) issued an update alleviating any potential impact from COVID-19, stating that it does not anticipate shortages for any of its products, including all forms of insulin. It also said it does not source any of its approved medicines from China, and that its insulin manufacturing sites in the United States and Europe have not been impacted by coronavirus.View more earnings on IBBIn pre-market trading Tuesday, the shares were adding 0.87% to $134 .Earnings Omeros Corporation's (NASDAQ: OMER) fourth-quarter revenues rose 12% to $33.4 million and the net loss widened from 48 cents per share to 58 cents per share.The stock added 17% to $14.73 in after-hours trading.Zogenix, Inc. (NASDAQ: ZGNX) reported fourth-quarter revenues of $1.95 million compared to no revenues a year ago. The net loss per share widened from 53 cents to $1.26. Analysts estimated a loss of $1.06 per share.The stock slipped 6.93% to $23.50 in after-hours trading.Precigen reported fourth-quarter revenues of $17 million, sharply lower than $41.19 million a year ago. The net loss, however, narrowed from $2.59 per share to $1.09 per share. Analysts expected a loss of 27 cents per share on 23.4 million.The stock declined 7.93% to $3.60 in after-hours trading.Offerings Close on the heels of reporting positive late-stage data for selinexor, Karyopharm announced the commencement of a registered underwritten public offering of $150 million worth of its common shares.The stock moved down 6.17% to $26.01 in after-hours trading.On The Radar Earnings * Antares Pharma Inc (NASDAQ: ATRS) (before the market open) * Autolus Therapeutics Ltd - ADR (NASDAQ: AUTL) (before the market open) * Neuronetics Inc (NASDAQ: STIM) (before the market open) * TG Therapeutics Inc common stock (NASDAQ: TGTX) (before the market open) * Sierra Oncology Inc (NASDAQ: SRRA) (before the market open) * Infinity Pharmaceuticals Inc. (NASDAQ: INFI) (after the close) * Syndax Pharmaceuticals Inc (NASDAQ: SNDX) (after the close) * VIVUS, Inc. (NASDAQ: VVUS) (after the close) * Voyager Therapeutics Inc (NASDAQ: VYGR) (after the close) * DURECT Corporation (NASDAQ: DRRX) (after the close) * Cytokinetics, Inc. (NASDAQ: CYTK) (after the close)See more from Benzinga * Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates * The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off * The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    Antares Pharma Reports Fourth Quarter and Full Year 2019 Operating and Financial Results

    Record Quarterly Revenue of $37.8 Million – Earnings Per Share of $0.03 Record Annual Revenue of $123.9 Million, a 95% Increase over 2018 Annual Revenue EWING, N.J., March.

  • Health Check: How Prudently Does Antares Pharma (NASDAQ:ATRS) Use Debt?
    Simply Wall St.

    Health Check: How Prudently Does Antares Pharma (NASDAQ:ATRS) Use Debt?

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

  • GlobeNewswire

    Antares Pharma to Present at the Cowen and Company 40th Annual Health Care Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Cowen and Company 40th Annual Health Care Conference on Wednesday March 4, 2020 at 11:20 am Eastern Time. Antares Pharma, Inc. is a combination drug device company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia).

  • GlobeNewswire

    Antares Pharma to Report Fourth Quarter and Full Year 2019 Financial and Operating Results

    Antares Pharma, Inc. (ATRS) today announced it will release its fourth quarter and full year 2019 financial results and recent operating progress before the market opens on Tuesday, March 3, 2020. Antares Pharma’s proprietary products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • GlobeNewswire

    Antares Pharma Announces Full-Year 2020 Net Revenue Guidance Range of $135 to $155 Million

    Antares Pharma, Inc. (ATRS) (The Company) today announced 2020 full-year net revenue guidance of $135 to $155 million, which includes a range of potential revenue scenarios for AMAG’s Makena. In addition, the Company also announced that full-year 2019 revenue is expected to be at the upper end or exceed our revenue guidance of $115 to $120 million.

  • Is Antares Pharma, Inc.'s (NASDAQ:ATRS) CEO Paid At A Competitive Rate?
    Simply Wall St.

    Is Antares Pharma, Inc.'s (NASDAQ:ATRS) CEO Paid At A Competitive Rate?

    In 2016 Bob Apple was appointed CEO of Antares Pharma, Inc. (NASDAQ:ATRS). First, this article will compare CEO...

  • Here is What Hedge Funds Think About Antares Pharma Inc (NASDAQ:ATRS)
    Insider Monkey

    Here is What Hedge Funds Think About Antares Pharma Inc (NASDAQ:ATRS)

    While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, increasing oil prices and deteriorating expectations towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the third quarter and hedging or reducing many of […]

  • GlobeNewswire

    Antares Pharma Appoints Edward Tykot Senior Vice President, Corporate Development

    Antares Pharma, Inc. (ATRS) today announced the appointment of Edward Tykot to the position of Senior Vice President, Corporate Development. Mr. Tykot is a seasoned corporate and business development executive with a proven record of success in both small and large pharmaceutical companies. Most recently, Mr. Tykot was Vice President, Business Development of Nevakar, Inc. Prior to Nevakar, Ed served as Vice President Business Development and Strategic Planning of Eagle Pharmaceuticals, Inc. where he was responsible for identifying and negotiating strategic opportunities for the organization.

  • GlobeNewswire

    Antares Pharma Social Media Campaign for XYOSTED® Wins MarCom Platinum Award

    The social media campaign for XYOSTED® featured a series of Facebook and Instagram ads to prime existing testosterone deficient patients for the launch of a new testosterone replacement therapy. The ads used humor and arresting imagery which focused on the challenges of other testosterone therapies such as messy application of testosterone gels and painful intramuscular injections. XYOSTED® is a once weekly, virtually painless subcutaneous injection of testosterone which can restore men’s testosterone levels into the normal range.

  • An Intrinsic Calculation For Antares Pharma, Inc. (NASDAQ:ATRS) Suggests It's 43% Undervalued
    Simply Wall St.

    An Intrinsic Calculation For Antares Pharma, Inc. (NASDAQ:ATRS) Suggests It's 43% Undervalued

    In this article we are going to estimate the intrinsic value of Antares Pharma, Inc. (NASDAQ:ATRS) by taking the...

  • GlobeNewswire

    Antares Pharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference on Tuesday December 3, 2019 at 2:00 pm, Eastern Time. Antares Pharma, Inc. is a combination drug device company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia).

  • Benzinga

    The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan ...

  • GlobeNewswire

    REMINDER: Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

    Selatogrel, a new chemical entity (NCE), is being developed for the treatment of a suspected acute myocardial infarction (AMI) in adult patients with a history of AMI. Idorsia’s Phase 2 clinical data demonstrated that subcutaneous administration of selatogrel resulted in a potent and rapid platelet inhibition effect in patients with a history of coronary artery disease and AMI.

  • GlobeNewswire

    Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

    Selatogrel, a new chemical entity (NCE), is being developed for the treatment of a suspected acute myocardial infarction (AMI) in adult patients with a history of AMI. Idorsia’s Phase 2 clinical data demonstrated that subcutaneous administration of selatogrel resulted in a potent and rapid platelet inhibition effect in patients with a history of coronary artery disease and AMI.

  • GlobeNewswire

    Antares Pharma to Present at the Jefferies 2019 London Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2019 London Healthcare Conference on Wednesday November 20, 2019, at 11:20 am (GMT) / 6:20 am (EST) in London, UK. Antares Pharma, Inc. is a combination drug device company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).

  • Thomson Reuters StreetEvents

    Edited Transcript of ATRS earnings conference call or presentation 5-Nov-19 1:30pm GMT

    Q3 2019 Antares Pharma Inc Earnings Call